Zelira Therapeutics Limited
ZLDAF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $40 | $55 |
| % Growth | -100% | -98.4% | -26.5% | – |
| Cost of Goods Sold | $801 | $3 | $323 | $1,160 |
| Gross Profit | -$801 | -$2 | -$283 | -$1,105 |
| % Margin | – | -321.7% | -703.7% | -2,019.3% |
| R&D Expenses | $1,253 | $1,412 | $1,567 | $1,244 |
| G&A Expenses | $619 | $1,035 | $934 | $1,351 |
| SG&A Expenses | $683 | $198 | $765 | $1,600 |
| Sales & Mktg Exp. | $4 | $9 | $0 | $20 |
| Other Operating Expenses | $0 | $0 | $0 | -$611 |
| Operating Expenses | $1,935 | $1,610 | $2,332 | $2,233 |
| Operating Income | -$2,736 | -$1,612 | -$2,835 | -$3,103 |
| % Margin | – | -246,094.7% | -7,047% | -5,670.9% |
| Other Income/Exp. Net | $1,371 | -$872 | -$502 | -$31,219 |
| Pre-Tax Income | -$1,365 | -$2,484 | -$3,337 | -$34,323 |
| Tax Expense | $0 | $0 | -$920 | $0 |
| Net Income | -$1,217 | -$2,411 | -$2,434 | -$34,135 |
| % Margin | – | -368,036.5% | -6,050.5% | -62,377.5% |
| EPS | -0.1 | -0.21 | -0.21 | -3.01 |
| % Growth | 52.4% | 0% | 93% | – |
| EPS Diluted | -0.1 | -0.21 | -0.21 | -3.01 |
| Weighted Avg Shares Out | 11,619 | 11,347 | 11,347 | 11,347 |
| Weighted Avg Shares Out Dil | 11,619 | 11,347 | 11,347 | 11,347 |
| Supplemental Information | – | – | – | – |
| Interest Income | $443 | $0 | $0 | $0 |
| Interest Expense | $0 | $851 | $528 | $211 |
| Depreciation & Amortization | $182 | $88 | $203 | $276 |
| EBITDA | -$2,677 | -$1,374 | -$2,606 | -$33,835 |
| % Margin | – | -209,712.4% | -6,478.3% | -61,829.6% |